There are 2867 resources available
Systemic therapeutic options
Presenter: Javier Cortés
Session: Oligometastatic disease and oligoprogression in breast cancer
Resources:
Slides
Webcast
Pro: PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer
Presenter: Yelena Janjigian
Session: PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer
Resources:
Slides
Webcast
The phase I perspective
Presenter: Ryan Sullivan
Session: Molecular tumor boards: Challenges in identifying personalised treatments for melanoma patients
Resources:
Slides
Webcast
Radiation
Presenter: Piet Ost
Session: Management of oligometastatic prostate cancer
Resources:
Slides
Webcast
Radiotherapy
Presenter: Sofia Rivera
Session: Oligometastatic disease and oligoprogression in breast cancer
Resources:
Slides
Webcast
Contra: PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer
Presenter: Raghav Sundar
Session: PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer
Resources:
Slides
Webcast
The oncologist’s perspective
Presenter: Omid Hamid
Session: Molecular tumor boards: Challenges in identifying personalised treatments for melanoma patients
Resources:
Slides
Webcast
Systemic therapy
Presenter: Silke Gillessen
Session: Management of oligometastatic prostate cancer
Resources:
Slides
Webcast
Surgery
Presenter: Elizabeth Mittendorf
Session: Oligometastatic disease and oligoprogression in breast cancer
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: All Speakers
Session: PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer
Resources:
Slides
Webcast